- Infection, human immunodeficiency virus
|
| |
| ABSOLUTE CONTRAINDICATIONS : |
| |
- >> Hypersensitivity reaction to abacavir
|
| |
| RELATIVE CONTRAINDICATIONS : |
| |
- Risk factors for hepatic disease
|
| |
- Hypersensitivity reaction
|
| |
- Hepatotoxicity , including lactic acidosis
|
| |
| |
| ADULT DOSE |
| |
| Human immunodeficiency virus (HIV) infection-Oral, 300 mg (base) two times a day, in combination with other antiretroviral agents . |
| MAXIMUM ADULT DOSE: |
| |
|
| PEDIATRIC DOSE : |
| |
| Human immunodeficiency virus (HIV) infection-Children up to 3 months of age: Safety and efficacy have not been established. Children 3 months to 16 years of age: Oral, 8 mg (base) per kg of body weight (up to 300 mg) two times a day, in combination with other antiretroviral agents .Children 16 years of age and older: See Usual adult and adolescent dose |
| MAXIMUM PEDIATRIC DOSE: |
| |
|
| GERIATRIC DOSE: |
| |
|
| PREGNANCY GROUP |
| |
| C |
| |